Ipamorelin Research Peptide 10 mg
For research use only. Not for human consumption.10 mg
$109.00
Pentapeptide, GHS-R ligand. CAS 170851-70-4.
A selective ghrelin-receptor (GHS-R1a) agonist studied as a growth-hormone secretagogue. Preclinical and limited Phase 2 research; not approved for any use.
Ordering is closed. This product becomes purchasable when a lot for it has been released and its certificate published.
Single-vial price. Volume pricing begins at 2 vials.
One unit is one vial. The per-vial price changes at 2, 6, 25, 50 and 100 vials; between those points it does not change.
An inquiry is a question about availability, never an order.
Below 100 vials the price is published, not quoted. The band your quantity falls into is applied automatically at checkout.
Research Use Only Purchasers must be 21+
Release requires
- Certificate of analysisNone on fileSigned by a named, independent, contactable laboratory.Why independence matters
- ChromatogramNone on fileFull trace as issued, not a redrawn summary.How a trace is read
- Identity confirmationNone on fileMethod and result as reported, never as summarised.Identity is not purity
- Lot recordNone on fileOne permanent address per lot, kept whatever the outcome.What a lot record holds
No purity figure, identity result, laboratory name or test date appears anywhere on this page, because none has been recorded for this product.
Description
Pentapeptide, sequence Aib-His-D-2-Nal-D-Phe-Lys-NH2. Also identified as NNC 26-0161. CAS 170851-70-4. Formula C38H49N9O5. Molecular weight 711.9 Da. Supplied as lyophilized powder, 10 mg per vial.
Learn the science Mechanism and pathway for Ipamorelin
A different door into the same axis
Ipamorelin acts on a different receptor from a GHRH analogue, and researchers have studied both as separate routes into growth-hormone release.
Ipamorelin
What you're seeing
A short laboratory-made peptide, five amino acids long, studied as a growth-hormone secretagogue: a substance that prompts the release of growth hormone.
Scientific detail
Sequence Aib-His-D-2-Nal-D-Phe-Lys-NH2. It was described in 1998 as the first selective growth hormone secretagogue, releasing growth hormone from primary rat pituitary cells with potency and efficacy comparable to the earlier peptide GHRP-6.
Where this happens
What you're seeing
The pituitary is a small gland at the base of the brain, and it is where growth hormone is made and stored. The receptor this compound acts on is found there.
Scientific detail
The 1998 characterisation cited below reported growth-hormone release from primary rat pituitary cells. The figure is a simplified orientation drawing marking that gland — not an anatomical illustration, and not to scale.
GHS-R1a
What you're seeing
The receptor that ghrelin — the hormone best known for hunger signaling — normally acts on. This is the step that makes ipamorelin mechanistically different from a GHRH analogue.
Scientific detail
Growth hormone secretagogue receptor, subtype 1a. A GHRH analogue such as tesamorelin acts on the separate GHRH receptor. Two different receptors, one shared downstream hormone: studying a selective agonist at this receptor is how researchers isolate this specific route from the other.
Pituitary signaling
What you're seeing
Activating the receptor sets off signaling in the pituitary gland, which is where growth hormone is made and stored.
Scientific detail
The selectivity reported in the original characterisation is the point of research interest: a secretagogue that acts on this receptor without broadly disturbing other pituitary hormones lets a study attribute what it observes to this pathway rather than to several at once.
Growth-hormone release
What you're seeing
The measurable end of the pathway. Human research on ipamorelin is limited, and it is not approved for any use.
Scientific detail
Pharmacokinetic and pharmacodynamic work in human volunteers has been published, along with preclinical work in a rodent model of post-operative ileus. A phase 2 trial in patients after abdominal surgery did not meet its endpoint, and development for that indication did not continue. Ipamorelin has never received FDA approval for any indication.
Simplified pathway, drawn for educational purposes. It shows what published research describes about the molecule. It does not describe a result in a person, and it is not a claim about NuePharma material.
Lot recordNo lot published yet
No lot published for this product yet. Nothing ships without a certificate.
Keep going
Go deeper into the science.
Discover the compounds, pathways and research systems connected to what you're already exploring.
Related research
-
Tesamorelin
For research use only. Not for human consumption.The GHRH-analogue route into the same growth-hormone axis — the comparison this page draws, seen from the other side.
Adjacent research pathways
-
Retatrutide
For research use only. Not for human consumption.Explore incretin and glucagon-receptor research, a separate part of the metabolic and endocrine picture.
Research systems Endocrine signaling
These are separate research materials with separate research records. Nothing here suggests combining them, and no connection above is a claim about using more than one.
Why this format
We intentionally selected this vial configuration as a balanced format for laboratory research—substantial enough for practical experimental planning without unnecessarily increasing the quantity contained in an individual vial. Each vial remains individually traceable to its corresponding lot record and supporting documentation.
Stability & storage
Refer to the product’s applicable documentation and labeled storage conditions. NuePharma does not assign generalized post-reconstitution or expiration periods unless supported by product-specific documentation.